Whistleblower Exposes Unprecedented Request for “Fentanyl Lollipops” by Top Border Patrol Medical Officer


In a revelation that has sent shockwaves through the Customs and Border Protection (CBP) agency, a whistleblower has come forward with allegations against Dr. Alexander Eastman, the acting chief medical officer. The report, submitted to Congress, accuses Dr. Eastman of pressuring staff members to procure fentanyl lollipops for use during the United Nations General Assembly held in New York in September. This request has raised eyebrows, given the potent nature of the Schedule II narcotics involved and the unusual context of their intended use.

Dr. Eastman, who assumed his role amidst a sudden shift in medical leadership following the tragic death of an 8-year-old girl in CBP custody, defended his actions by stating the necessity of having such pain management solutions on hand. He argued that the fentanyl lollipops were meant for emergency situations where CBP agents or others might require immediate and effective pain relief. However, this explanation has not quelled concerns about the appropriateness and legality of his request.

The whistleblowers highlighted that Dr. Eastman’s insistence on acquiring these narcotics consumed significant time and resources of the Office of the Chief Medical Officer (OCMO) staff. Despite their efforts, they were ultimately unable to fulfill the request due to the inability to find a vendor in time for the event. This situation has led to further scrutiny of Dr. Eastman’s judgment and the protocols surrounding the procurement and use of controlled substances within the agency.

Adding to the controversy, it was revealed that Dr. Eastman was under investigation by CBP’s Office of Professional Responsibility at the time regarding the improper ordering and securing of narcotics for a friend who is a pilot for Air and Marine Operations. This friend was actively working as a helicopter pilot in New York during the General Assembly, raising questions about the potential misuse of government resources and narcotics.

In response to these serious allegations, a CBP spokesperson stated that the agency takes all claims of misconduct seriously and has referred the matter to the CBP Office of Professional Responsibility for review. The agency has committed to transparency and accountability, promising updates as the investigation progresses.

Dr. Eastman’s background as a highly decorated officer and medical professional, including his roles within the Department of Homeland Security and his involvement in national planning for law enforcement medical support, makes these allegations particularly troubling. His previous honors and awards underscore the gravity of the situation and the importance of a thorough and unbiased investigation.

The implications of these allegations extend beyond the individual involved, highlighting potential vulnerabilities in the oversight and management of narcotics within federal agencies. It underscores the need for stringent policies and procedures to prevent misuse and ensure that all actions taken by officials are in the best interest of public safety and welfare.

As the investigation unfolds, many are calling for a reevaluation of protocols related to the procurement and use of controlled substances by government officials. Ensuring the integrity and accountability of those in positions of power is paramount to maintaining public trust and the effective operation of our nation’s security apparatus.